Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more ...

Acute myocardial infarction and acute kidney injury are life-threatening conditions caused by ischemia, resulting from reduced or blocked blood flow to organs. Although early restoration of blood flow ...

The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. In an ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

A pioneering study by researchers from Finland and the UK has demonstrated for the first time that myocardial infarction may be an infectious disease. This discovery challenges the conventional ...

Resolution of steatohepatitis with no worsening of liver fibrosis was achieved in 63% of patients taking semaglutide vs 34% taking placebo at week 72. The Food and Drug Administration (FDA) has ...

Approval was based on part 1 of the ESSENCE trial, with part 2 results expected in 2029. At 72 weeks, about 63% of participants treated with semaglutide achieved resolution of steatohepatitis without ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by ...

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. The FDA has signed off on ...